GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans.
eicosanoids
epoxide hydrolases
hypertension
insulin resistance
oxidative stress
Journal
Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
31
8
2021
medline:
14
1
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
[Figure: see text].
Identifiants
pubmed: 34455816
doi: 10.1161/HYPERTENSIONAHA.121.17659
pmc: PMC8429121
mid: NIHMS1728867
doi:
Substances chimiques
Cyclohexylamines
0
F2-Isoprostanes
0
N-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide
0
Triazines
0
Epoxide Hydrolases
EC 3.3.2.-
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1092-1102Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002245
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007569
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK117875
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020593
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024975
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK114809
Pays : United States
Références
N Engl J Med. 1995 May 4;332(18):1198-203
pubmed: 7700313
J Biol Chem. 2014 Feb 14;289(7):4377-86
pubmed: 24368771
J Biol Chem. 2013 May 17;288(20):14189-14199
pubmed: 23576437
Cell Physiol Biochem. 2015;35(5):2043-54
pubmed: 25870948
Vascul Pharmacol. 2015 Nov;74:23-37
pubmed: 26363473
Annu Rev Pharmacol Toxicol. 2013;53:37-58
pubmed: 23020295
Circ Res. 1996 Mar;78(3):415-23
pubmed: 8593700
J Pharmacol Exp Ther. 2010 Aug;334(2):430-8
pubmed: 20439437
Clin Sci (Lond). 2007 Aug;113(3):141-8
pubmed: 17425514
Mol Cell Proteomics. 2015 Oct;14(10):2764-74
pubmed: 26070664
Diabetes. 1992 Mar;41(3):354-8
pubmed: 1551495
Hypertension. 2015 Mar;65(3):476-82
pubmed: 25583156
Hypertension. 2011 Jan;57(1):116-22
pubmed: 21098312
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9038-43
pubmed: 21571638
J Clin Pharmacol. 2012 Mar;52(3):319-28
pubmed: 21422238
Clin Nephrol. 1980 Jan;13(1):26-9
pubmed: 7363512
Diabetologia. 2017 Jun;60(6):1066-1075
pubmed: 28352940
Hypertension. 2006 Dec;48(6):1050-7
pubmed: 17043157
Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:42-8
pubmed: 23247129
J Cell Physiol. 1990 Sep;144(3):429-37
pubmed: 2167900
Exp Diabetes Res. 2012;2012:758614
pubmed: 22007192
Eur J Clin Invest. 1995 Jan;25(1):39-43
pubmed: 7705385
J Lipid Res. 2012 Mar;53(3):456-466
pubmed: 22223859
Br J Clin Pharmacol. 2016 May;81(5):971-9
pubmed: 26620151
Chest. 2017 Mar;151(3):555-563
pubmed: 27884766
Obesity (Silver Spring). 2010 Mar;18(3):489-98
pubmed: 19644452
PLoS One. 2012;7(6):e39165
pubmed: 22720061
J Pharmacol Exp Ther. 2009 Dec;331(3):906-16
pubmed: 19717790
Metabolism. 2004 Sep;53(9):1118-20
pubmed: 15334370
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Science. 1999 Aug 20;285(5431):1276-9
pubmed: 10455056
Prostaglandins Other Lipid Mediat. 2014 Oct;113-115:38-44
pubmed: 25173047
Am J Physiol Endocrinol Metab. 2014 Dec 15;307(12):E1097-104
pubmed: 25336524
Stem Cells Dev. 2010 Dec;19(12):1863-73
pubmed: 20412023
Biotechniques. 2007 Jul;43(1 Suppl):25-30
pubmed: 17936939
Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):3-8
pubmed: 21040800